The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Carl B

Carl Borrebaeck

Professor

Carl B

Testing human skin and respiratory sensitizers—what is good enough?

Author

  • Anki Malmborg
  • Carl A K Borrebaeck

Summary, in English

Alternative methods for accurate in vitro assessment of skin and respiratory sensitizers are urgently needed. Sensitization is a complex biological process that cannot be evaluated accurately using single events or biomarkers, since the information content is too restricted in these measurements. On the contrary, if the tremendous information content harbored in DNA/mRNA could be mined, most complex biological processes could be elucidated. Genomic technologies available today, including transcriptional profiling and next generation sequencing, have the power to decipher sensitization, when used in the right context. Thus, a genomic test platform has been developed, denoted the Genomic Allergen Rapid Detection (GARD) assay. Due to the high informational content of the GARD test, accurate predictions of both the skin and respiratory sensitizing capacity of chemicals, have been demonstrated. Based on a matured dendritic cell line, acting as a human-like reporter system, information about potency has also been acquired. Consequently, multiparametric diagnostic technologies are disruptive test principles that can change the way in which the next generation of alternative methods are designed.

Department/s

  • Department of Immunotechnology

Publishing year

2017-02-01

Language

English

Publication/Series

International Journal of Molecular Sciences

Volume

18

Issue

2

Document type

Journal article

Publisher

MDPI AG

Topic

  • Cell and Molecular Biology
  • Respiratory Medicine and Allergy

Keywords

  • Adverse outcome pathways
  • Genomics
  • Next generation in vitro tests
  • Skin sensitization

Status

Published

ISBN/ISSN/Other

  • ISSN: 1661-6596